Rethinking the burden of latent tuberculosis to reprioritize research

Marcel A Behr¹, Paul H Edelstein^{2

3}, Lalita Ramakrishnan^{4

5}

Affiliations

¹ Department of Medicine, McGill University, McGill International TB Centre, Montreal, Quebec, Canada.
² Department of Medicine, University of Cambridge, Cambridge, UK.
³ MRC Laboratory of Molecular Biology, Cambridge, UK.
⁴ Department of Medicine, University of Cambridge, Cambridge, UK. lalitar@mrc-lmb.cam.ac.uk.
⁵ MRC Laboratory of Molecular Biology, Cambridge, UK. lalitar@mrc-lmb.cam.ac.uk.

Marcel A Behr et al. Nat Microbiol. 2024 May.

. 2024 May;9(5):1157-1158.

doi: 10.1038/s41564-024-01683-0.

Marcel A Behr¹, Paul H Edelstein^{2

3}, Lalita Ramakrishnan^{4

5}

¹ Department of Medicine, McGill University, McGill International TB Centre, Montreal, Quebec, Canada.
² Department of Medicine, University of Cambridge, Cambridge, UK.
³ MRC Laboratory of Molecular Biology, Cambridge, UK.
⁴ Department of Medicine, University of Cambridge, Cambridge, UK. lalitar@mrc-lmb.cam.ac.uk.
⁵ MRC Laboratory of Molecular Biology, Cambridge, UK. lalitar@mrc-lmb.cam.ac.uk.

No abstract available

References

1. Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Br. Med. J. 362, k2738 (2018). - DOI
1. Global Tuberculosis Report 2021 (WHO, 2021); https://go.nature.com/3re4n6j
1. Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis M72 Vaccine Candidate That Could Be the First in 100 Years if Proven Effective (Bill & Melinda Gates Foundation, 2023); https://go.nature.com/3VVlv8L
1. Nat. Microbiol. 8, 1601–1602 (2023).
1. Tozer, L. Nature https://doi.org/10.1038/d41586-023-02171-x (2023).